ADC Introduction

Antibody drug conjugates are now a viable and effective therapy for some diseases including cancer and hematological diseases. Four drugs have already been approved and there are more than 60 others in the clinical trial pipeline. The major approach is to target cancer cells directly by linking high potency chemicals (eg. derivatives of toxins) onto monoclonal antibodies. This approach enhances potency and reduces toxic side effects by targeting the monoclonal antibody to specific cells. There are three key components in developing ADC: a specific monoclonal antibody, a high potency chemical, and an effective linker. EirGenix's major business is to support our clients’ biologics development by providing the best monoclonal antibodies, high potency chemicals, and effective linkers in an integrated service platform.

End to End ADC/Bioconjugates Services

Monoclonal Antibody Development and Production

Antibodies, with their precise targeting capabilities, serve as essential carriers in the development of antibody-drug conjugates (ADCs). EirGenix offers end-to-end support for antibody development, encompassing both non-GMP and GMP-level manufacturing. Leveraging our Eirgenix/Formosa Laboratories service platform, we can perform early-stage compatibility studies across antibodies, intermediates, payloads, and linkers in parallel. This integrated approach ensures that all critical components are optimized for seamless and efficient process development, accelerating the path from concept to clinical-ready conjugates.

High Potency Chemicals

Formosa Laboratories, a strategic partner of EirGenix, is a global leader in high-potency drug manufacturing, supplying top-quality active pharmaceutical ingredients (APIs) to the US, EU, and other key markets worldwide. With a dedicated team of 58 chemists, 9 granted process patents, and 22 patents under review, Formosa combines cutting-edge innovation with robust manufacturing capabilities. Its advanced facilities—including 50–1,000 L stainless steel reactors, equally scaled chromatography columns, isolators (glove boxes), and 280 L falling film evaporators—support a production capacity of up to 2,000 L for high-potency APIs. These capabilities enable Formosa Laboratories to provide fully integrated services for the research, development, and manufacturing of high-potency compounds for ADCs, ensuring reliability, efficiency, and quality for clients across the globe.

Linkers

Linkers are a key component in ADC.An effective linker needs to be stable in the circulatory system, but easily broken down in the target cells. EirGenix has partnered with the leading linker development companies. Combined with the capability of EirGenix and Formosa Laboratories, we are the best partner for client's ADC development and manufacturing project.